About Ayala

We are a clinical-stage oncology company founded in November 2017 after acquiring an exclusive, worldwide license to our product candidates, AL101 and AL102, from Bristol-Myers Squibb. We’re focused on developing and commercializing potentially best-in-class small molecule therapeutics for patients suffering from rare and aggressive cancers, especially in genetically defined patient populations.

What makes us different lies in our development approach. It’s rooted in identifying and addressing indications in which Notch is a known tumorigenic driver, using a combination of our bioinformatics platform and next-generation sequencing to help deliver targeted therapies to underserved patient populations. Advances in molecular testing and sequencing have enabled the discovery of Notch-activating mutations in multiple tumor types – this provides us with additional tools to identify the patients that are most likely to respond to the gamma secretase inhibitors that we are developing.

How our therapies can help

Our product candidates, AL101 and AL102, are designed to target cancer by addressing the underlying key drivers of tumor growth. Both product candidates target the aberrant activation of the Notch pathway with gamma secretase inhibitors (GSIs). Gamma secretase is the enzyme responsible for Notch activation and, when inhibited, turns off the Notch pathway activation.

By developing drugs designed to inhibit Notch pathway activation, we’re enabling personalized therapy for cancer patients. Currently, we have two product candidates in development for a variety of cancers:

Adenoid Cystic Carcinoma (ACC)
Triple Negative Breast Cancer (TNBC)
T-cell Acute Lymphoblastic Leukemia (T-ALL)
Desmoid Tumors

In addition to Notch pathway, gamma secretase may be targeted to increase levels of B-cell maturation antigen (BCMA), which is expressed in most multiple myeloma patients. Therefore, AL102 is being studied to evaluate its clinical role in enhancing anti-BCMA therapies in Multiple Myeloma (MM), in collaboration with Novartis.

Learn more

The history of the Notch pathway

Aberrant activation of the Notch pathway has long been connected to multiple solid tumors and hematological cancers, and has often been associated with more aggressive cancers. In cancers, Notch is known to serve as a critical facilitator in processes such as cellular proliferation, survival, migration, invasion, drug resistance and metastatic spread, which all contribute to poorer patient outcomes.

Learn about our pipeline
How notch signaling works

Our mission

At Ayala, we are focused on developing best-in-class targeted therapies for people with cancer in whom the Notch pathway is activated. We target genetically defined, clinically underserved cancers where we can have the most impact.

We are guided by strongly held values:


Improve treatment outcomes for patients with aggressive cancers


Be compassionate to the patients we serve


Be open, honest, and ethical in all our endeavors – always


Bring innovative products to market efficiently, for the benefit of our patients


Work with patients, physicians and support groups to develop meaningful treatment advancements

Our people

Ayala is proudly driven by established biotech leaders with proven experience in building and operating clinical and commercial organizations, particularly in oncology and rare diseases.